David A. Siegel Werewolf Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 247,600 shares of HOWL stock, worth $604,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
247,600
Previous 177,300
39.65%
Holding current value
$604,144
Previous $684,000
134.5%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HOWL
# of Institutions
65Shares Held
26.1MCall Options Held
2.4KPut Options Held
35K-
Mpm Asset Management LLC Cambridge, MA4.28MShares$10.5 Million11.32% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.01MShares$7.34 Million0.96% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$7.32 Million0.04% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$5.83 Million2.53% of portfolio
-
Bank Of America Corp Charlotte, NC1.88MShares$4.59 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $72.1M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...